Literature DB >> 18350603

Tumor suppressor and hepatocellular carcinoma.

Juliette Martin1, Jean-Francois Dufour.   

Abstract

A few signaling pathways are driving the growth of hepatocellular carcinoma. Each of these pathways possesses negative regulators. These enzymes, which normally suppress unchecked cell proliferation, are circumvented in the oncogenic process, either the over-activity of oncogenes is sufficient to annihilate the activity of tumor suppressors or tumor suppressors have been rendered ineffective. The loss of several key tumor suppressors has been described in hepatocellular carcinoma. Here, we systematically review the evidence implicating tumor suppressors in the development of hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18350603      PMCID: PMC2695912          DOI: 10.3748/wjg.14.1720

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  196 in total

1.  Loss of E-cadherin mRNA and gain of osteopontin mRNA are useful markers for detecting early recurrence of HCV-related hepatocellular carcinoma.

Authors:  Yukihiro Iso; Tokihiko Sawada; Toshie Okada; Keiichi Kubota
Journal:  J Surg Oncol       Date:  2005-12-15       Impact factor: 3.454

2.  Genetic inactivation of the APC gene contributes to the malignant progression of sporadic hepatocellular carcinoma: a case report.

Authors:  Hiroto Katoh; Tatsuhiro Shibata; Akiko Kokubu; Hidenori Ojima; Tomoo Kosuge; Yae Kanai; Setsuo Hirohashi
Journal:  Genes Chromosomes Cancer       Date:  2006-11       Impact factor: 5.006

Review 3.  p53 gene in treatment of hepatic carcinoma: status quo.

Authors:  Yong-Song Guan; Zi La; Lin Yang; Qing He; Ping Li
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

4.  Geographic variation of p53 mutational profile in nonmalignant human liver.

Authors:  F Aguilar; C C Harris; T Sun; M Hollstein; P Cerutti
Journal:  Science       Date:  1994-05-27       Impact factor: 47.728

5.  Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.

Authors:  Y Ito; N Matsuura; M Sakon; E Miyoshi; K Noda; T Takeda; K Umeshita; H Nagano; S Nakamori; K Dono; M Tsujimoto; M Nakahara; K Nakao; N Taniguchi; M Monden
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

6.  Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein.

Authors:  In Young Park; Bo Hwa Sohn; Eunsil Yu; Dong Jin Suh; Young-Hwa Chung; Je-Ho Lee; Stefan J Surzycki; Young Ik Lee
Journal:  Gastroenterology       Date:  2007-01-25       Impact factor: 22.682

7.  Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis.

Authors:  Ke-Jun Nan; Zhi-Ping Ruan; Zhao Jing; Hai-Xia Qin; Hong-Yan Wang; Hui Guo; Rui Xu
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

8.  Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma.

Authors:  Hung-Wei Pan; Han-Yi E Chou; Shu-Hsiang Liu; Shian-Yang Peng; Chao-Lien Liu; Hey-Chi Hsu
Journal:  Cell Cycle       Date:  2006-11-15       Impact factor: 4.534

9.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

10.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Authors:  Laura Gramantieri; Manuela Ferracin; Francesca Fornari; Angelo Veronese; Silvia Sabbioni; Chang-Gong Liu; George A Calin; Catia Giovannini; Eros Ferrazzi; Gian Luca Grazi; Carlo M Croce; Luigi Bolondi; Massimo Negrini
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

View more
  32 in total

Review 1.  Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes.

Authors:  Yuan-Chi Teng; Zhao-Qing Shen; Cheng-Heng Kao; Ting-Fen Tsai
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  FXR-Gankyrin axis is involved in development of pediatric liver cancer.

Authors:  Leila Valanejad; Kyle Lewis; Mary Wright; Yanjun Jiang; Amber D'Souza; Rebekah Karns; Rachel Sheridan; Anita Gupta; Kevin Bove; David Witte; James Geller; Gregory Tiao; David L Nelson; Lubov Timchenko; Nikolai Timchenko
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

3.  RNA Binding Protein CUGBP1 Inhibits Liver Cancer in a Phosphorylation-Dependent Manner.

Authors:  Kyle Lewis; Leila Valanejad; Ashley Cast; Mary Wright; Christina Wei; Polina Iakova; Lauren Stock; Rebekah Karns; Lubov Timchenko; Nikolai Timchenko
Journal:  Mol Cell Biol       Date:  2017-07-28       Impact factor: 4.272

4.  Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss.

Authors:  Shelli M Morris; Ji Yeon Baek; Amanda Koszarek; Samornmas Kanngurn; Sue E Knoblaugh; William M Grady
Journal:  Hepatology       Date:  2011-12-06       Impact factor: 17.425

5.  Targeted deletion of hepatocyte Ikkbeta confers growth advantages.

Authors:  Katherine S Koch; Shin Maeda; Guobin He; Michael Karin; Hyam L Leffert
Journal:  Biochem Biophys Res Commun       Date:  2009-01-24       Impact factor: 3.575

6.  Targeted p21WAF1/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells.

Authors:  Mika Kosaka; Moo Rim Kang; Glen Yang; Long-Cheng Li
Journal:  Nucleic Acid Ther       Date:  2012-08-21       Impact factor: 5.486

7.  Novel therapeutic approaches for hepatocellulcar carcinoma: fact and fiction.

Authors:  Yuan-Yuan Zhang; Harry-Hua-Xiang Xia
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

8.  The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.

Authors:  Baoying Hu; Yicheng Xiong; Runzhou Ni; Lixian Wei; Dawei Jiang; Gang Wang; Di Wu; Tianxin Xu; Fengbo Zhao; Mingyan Zhu; Chunhua Wan
Journal:  Mol Cell Biochem       Date:  2014-08-01       Impact factor: 3.396

9.  Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis.

Authors:  Hyun Jin Song; Xinyi Jiang; Linda Henry; Mindie H Nguyen; Haesuk Park
Journal:  Eur J Clin Pharmacol       Date:  2020-03-14       Impact factor: 2.953

10.  Disruption of tumor suppressor gene Hint1 leads to remodeling of the lipid metabolic phenotype of mouse liver.

Authors:  Diren Beyoğlu; Kristopher W Krausz; Juliette Martin; Olivier Maurhofer; Juliane Dorow; Uta Ceglarek; Frank J Gonzalez; Jean-François Dufour; Jeffrey R Idle
Journal:  J Lipid Res       Date:  2014-09-05       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.